High plasma heparin cofactor II activity protects from restenosis after femoropopliteal stenting

Summary

High heparin cofactor II (HCII) activity has recently been described to protect from coronary instent restenosis, presumably by inactivating thrombin in injured arteries. In this study, we investigated the association of HCII activity and restenosis after femoropopliteal stenting. We studied 63 consecutive patients with peripheral artery disease who underwent femoropopliteal stent implantation after initial failure of plain balloon angioplasty due to a significant residual stenosis (>30% lumen diameter reduction) or a flow limiting dissection. HCII activity was measured before stenting and patients were followed for median 10 months (interquartile range 6 to 17) for the occurrence of a first instent restenosis, defined as a >50% lumen diameter reduction by color coded duplex sonography and confirmed by angiography. Cumulative freedom from restenosis at 6 and 12 months in patients with lower HCII activity (≤100%, lower tertile, n=20) was 84% and 35% as compared to 93% and 72% in patients with high HCII activity (>100%, middle and upper tertile, n=43; p=0.024 by Log Rank test). Adjusting for the material of the implanted stents (nitinol vs.Wallstents), patients with a high HCII activity had a 0.39-fold reduced risk for instent restenosis (95% CI 0.17 to 0.90, p=0.028), additional adjustment for diabetes mellitus, poor run-off, critical limb ischemia and cumulative length of the stented segment did not alter the observed effect. Higher activity of heparin cofactor II may exert a protective effect against instent restenosis also in the femoropopliteal vessel area, confirming a prior observation after coronary stenting.

Keywords

Percutaneous - angioplasty - stents - restenosis - heparin cofactor II

• References

• 1 Takamori N, Azuma H, Kato M. et al. High plasma heparin cofactor II activity is associated with reduced incidence of in-stent restenosis after percutaneous coronary intervention. Circulation 2004; 109: 481-6.
• 2 DiCorleto PE. Cellular mechanisms of atherogenesis. Am J Hypertens 1993; 06: 314S-318S.
• 3 Wilensky RL, Pyles JM, Fineberg N. Increased thrombin activity correlates with increased ischemic event rate after percutaneous transluminal coronary angioplasty: lack of efficacy of locally delivered urokinase. Am Heart J 1999; 138: 319-25.
• 4 Tollefsen DM. Insights into the mechanism of action of heparin cofactor II. Thromb Haemost 1995; 74: 1209-14.
• 5 Tammi M, Seppala PO, Lehtonen A. et al. Connective tissue components in normal and atherosclerotic human coronary arteries. Atherosclerosis 1978; 29: 191-4.
• 6 Henry M, Amor M, Beyar I. et al. Clinical experience with a new nitinol self-expanding stent in peripheral artery disease. J Endovasc Surg 1996; 03: 369-79.
• 7 Vroegindeweij D, Vos LD, Tielbeek AV. et al. Balloon angioplasty combined with primary stenting versus balloon angioplasty alone in femoropopliteal obstructions: A comparative randomized study. Cardiovasc Intervent Radiol 1997; 20: 420-5.
• 8 Zdanowski Z, Albrechtsson U, Lundin A. et al. Percutaneous transluminal angioplasty with or without stenting for femoropopliteal occlusions? A randomized controlled study. Int Angiol 1999; 18: 251-5.
• 9 Cejna M, Turnher S, Illiasch H. et al. PTA versus Palmaz stent in femoropopliteal artery obstructions: a multicenter prospective randomized study. J Vasc Intervent Radiol 2001; 12: 23-31.
• 10 Grimm J, Muller-Hulsbeck S, Jahnke T. et al. Randomized study to compare PTA with Palmaz stent placement for femoropopliteal lesions. J Vasc Intervent Radiol 2001; 12: 935-42.
• 11 Farb A, Sangiorgi G, Carter AJ. et al. Pathology of acute and chronic coronary stenting in humans. Circulation 1999; 99: 44-52.
• 12 Komatsu R, Ueda M, Naruko T. et al. Neointimal tissue response at site of coronary stenting in humans: macroscopic, histological, and immunohistochemical analyses. Circulation 1998; 98: 224-33.
• 13 Ranke C, Creutzig A, Alexander K. Duplex scanning of the peripheral arteries: correlation of the peak velocity ratio with angiographic diameter reduction. Ultrasound Med Biol 1992; 18: 433-40.
• 14 Aihara K, Azuma H, Takamori N. et al. Heparin cofactor II is a novel protective factor against carotid atherosclerosis in elderly individuals. Circulation 2004; 109: 2761-5.
• 15 Derian CK, Damiano BP, D´Andrea MR. et al. Thrombin regulation of cell function through protease-activated receptors: implications for therapeutic intervention. Biochemistry 2002; 67: 56-64.
• 16 Buchanan MR, Brister SJ. Inhibition of chronic vessel wall intimal hyperplasia following acute anticoagulant treatment: relative effects of heparin and dermatan sulfate. Thromb Res 1998; 91: 157-67.
• 17 Yamanaga K, Yuuki T, Tsukada M. et al. Heparin cofactor II inhibits thrombus formation in a rat thrombosis model. Thromb Res 2000; 98: 95-101.
• 18 He L, Vicente CP, Westrick RJ. et al. Heparin cofactor II inhibits arterial thrombosis after endothelial injury. J Clin Invest 2002; 109: 213-9.